Table 4
Adverse event summary
| Fixed combination latanoprost/timolol (n = 165) | Unfixed combination brimonidine/timolol (n = 167) | |||
|---|---|---|---|---|
| n | % | n | % | |
| No adverse event | 126 | 76.4 | 126 | 75.5 |
| At least one adverse event | 39 | 23.6 | 41 | 24.6 |
| Ocular adverse event(s) | 29 | 17.6 | 34 | 20.4 |
| Systemic adverse event(s) | 14 | 8.5 | 13 | 7.8 |
| Adverse event(s) related to study medication | 12 | 7.3 | 31 | 18.6 |
| Discontinuation due to adverse event(s) | 3 | 1.8 | 18 | 10.8 |
| Serious adverse event(s) | 4 | 2.4 | 1 | 0.6 |
